Pfizer CEO: Company will submit data for children's vaccine to FDA in "days"

• Earlier this week, Pfizer announced that results from its pediatric trial indicate that its vaccine — in a smaller dosage than given to adults — is safe and effective for children ages 5 to 11.

What he's saying: "I think we're going to submit this data pretty soon. It's a question of days, not weeks," Bourla said.

• "Then it is up to the FDA to be able to review the data and come to their conclusions, and approve it or not."
• "If they approve it, we will be ready with our manufacturing to provide this new formulation of the vaccine," Bourla said.

Go deeper: Pfizer coronavirus vaccine safe, effective in children, company says